Why the study?
While calcium channel blockers are often recommended as first-line therapy for hypertension, their effect on preventing cardiovascular events compared with other antihypertensive drug classes remains debated.
Does first-line therapy with calcium channel blockers reduce major adverse cardiovascular events in patients with hypertension compared to other antihypertensive drug classes?
Population
153,849 participants with hypertension across 23 RCTs
Comparison
First-line CCBs vs other antihypertensive drug classes
Design
Systematic review and meta-analysis of RCTs
Follow-up
At least two years
Loading...
CCBs show mixed efficacy versus other antihypertensives with moderate-weak certainty; leaves optimal first-line choice open pending stronger trials.
Does first-line therapy with calcium channel blockers reduce major adverse cardiovascular events in patients with hypertension compared to other antihypertensive drug classes?
As first-line therapy for hypertension, calcium channel blockers are inferior to diuretics for preventing major cardiovascular events and heart failure, but superior to beta-blockers for reducing major cardiovascular events and stroke.
A 2022 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: